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ABSTRACT
Background. International guidelines recommend the use of cardiac troponin assays for early detection of 
acute myocardial infarction. New high-sensitivity assays along with improved precision and sensitivity, are 
now widely available, accelerating patient’s diagnosis, treatment and invasive therapy.  In this study we 
evaluated analytical performance of the Abbott ARCHITECT STAT high-sensitive troponin-I immunoassay 
and its 99th percentile upper reference limit. 
Methods. We performed the analytical evaluation of the hs-cTnI assay using Abbott ARCHITECT i2000SR 
immunoanalyzers. Features of the assay including imprecision, detection limits, linearity of dilution, inter-
ferences and method comparisons were assessed, as well as the 99th percentile upper reference limits 
in a cohort of 427 presumably healthy individuals were established. 
Results. Total imprecision ranged from 3.1% to 4.7% and was lowest for the medium controls. The observed 
limit of blank, limit of detection and limit of quantitation assumed values of 0.1, 1.5 and 4.8 ng/L, respec-
tively. Common interferences, sample dilution and carry over did not affect the hs-cTnI results. Hs-cTnI 
was detectable in 98% of presumably healthy individuals. The 99th percentile values were age and sex 
dependent in the presumably healthy, but not in the healthy individuals.
Conclusion. The new high-sensitivity troponin-I assay has improved analytical features and may be 
a valuable diagnostic tool. 
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Introduction
The primary role for cardiac troponin (cTn) assays, 
since its introduction have been to diagnose patients 
with acute myocardial infarction (AMI) [1–3]. Due to 
this, international guidelines recommend the use of 
high-sensitivity cTn (hs-cTn) assays for early detection 
of AMI [3]. New high-sensitivity assays with improved 
precision and sensitivity are now widely available im-
proving the ability to detect cardiomyocyte injury and 
accelerating patient’s diagnosis, treatment and invasive 
therapy [4]. Another advantage of hs-cTnI assays, in 
addition to a rapid diagnosis of patients with suspect-
ed acute coronary syndromes (ACS), is the ability to 
measure the concentrations of cTn in the majority of 
healthy individuals, which may contribute to its role 
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in primary prevention and long-term assessment of 
adverse events. 
The study was designed and supervised in the 
Department of Laboratory Medicine in cooperation 
with clinicians from the Department of Cardiology and 
Internal Medicine, Collegium Medicum in Bydgoszcz, 
Nicolaus Copernicus University in Torun.  Laboratory 
tests were performed in the Department of Laboratory 
Medicine, Antoni Jurasz University Hospital No. 1 in 
Bydgoszcz, which is the region’s largest specialized 
medical facility and is of regional importance. The hospi-
tal’s organizational structure consists of 26 departments 
and units (940 beds in total), 6 diagnostic divisions 
and specialist outpatient clinics. The hospital annually 
admits approximately 37,000 patients and providing 
170,000 specialist consultations.
The Department of Laboratory Medicine is part of 
Antoni Jurasz University Hospital and is headed by 
Professor Grażyna Odrowąż-Sypniewska. For the last 
10 years the laboratory has participated in the Randox 
International Quality Assessment Scheme (RIQAS) 
and in the Central National Laboratory Program, and 
is certified by these bodies.
The laboratory is equipped with high quality medical 
equipment enabling us to perform tests in the fields of 
clinical chemistry, immunochemistry, hematology, body 
fluid analysis, toxicology, allergology and other highly 
specialized research.
The purpose of the study was:
1. To evaluate the analytical performance of the Abbott 
ARCHITECT STAT High Sensitive Troponin-I assay 
following CLSI guidelines EP5-A2 for precision [5], 
EP17-A for limit of blank (LoB), limit of detection 
(LoD) and limit of quantitation (LoQ) [6] and 
EP6-A for linearity [7] on the ARCHITECT ci8200.
2. To establish the 99th percentile upper reference 
limit (URL) for hs-cTnI in presumably healthy and 
healthy individuals.
3. To compare specimen results obtained with the 
Abbott ARCHITECT STAT High Sensitive Troponin-I 
assay with the ARCHITECT STAT Troponin-I assay 
using a minimum of 150 specimens with cTnI con-
centrations across the dynamic range of the assay.
Materials and methods
Study design and performance 
After the study protocol was approved by the 
Bioethics Committee of the Collegium Medicum, 
Nicolaus Copernicus University in Torun, we started 
recruiting presumably healthy subjects. Blood sam-
pling was carried out in several workplaces across the 
region. Serum and plasma samples were obtained 
from presumably healthy individuals who declared 
good health in the questionnaires, completed by 
each individual prior to sampling. The presumably 
healthy reference population was defined as indi-
viduals who were free of cardiac diseases (had no 
history of cardiac disease, cardiac treatment, cardiac 
intervention), hypertension, diabetes mellitus or hyper-
lipidemia. Additionally, the following inclusion criteria 
were defined as follows: BNP < 25 pg/mL for males 
and < 40 pg/mL for females; eGFR > 90 mL/min for 
aged below 40 and > 60 mL/min for those aged over 41; 
HbA1c < 6.5%. Dyslipidemia was defined by at least one 
abnormal level of serum lipid parameters: total choles-
terol (TC) > 200 mg/dL, triglyceride (TG) > 150 mg/dL, 
LDL-cholesterol (LDL-C) > 130 mg/dL, HDL-cholesterol 
(HDL-C) < 50 mg/dL for women and < 40 mg/dL for 
men according to the modified definition in the Third Re-
port of the National Cholesterol Education Program [8]. 
Hypertension was diagnosed if systolic blood pressure 
exceeded 140 mm Hg and/or diastolic blood pressure 
was above 90 mm Hg. Blood pressure measurements 
were obtained if needed. Additional exclusion criteria 
included pregnancy, current infection and chronic 
inflammatory disease. 
The 99th percentile values for hs-cTnI in a reference 
population were determined in two defined groups: 
presumably healthy and healthy, respectively. The 
427 participants were defined as presumably healthy 
on the basis of criteria from a health questionnaire. 
We initially excluded eight individuals who did not 
meet the inclusion criteria in the study, 3 of them were 
identified as outliers. The final study group consisted 
of 418 presumably healthy subjects (265 females and 
153 males, aged 17–74). The next step of our analy-
sis included 320 healthy subjects (212 females and 
108 males, aged 17–65) who fulfilled the requirements 
of the study according to the main inclusion and ex-
clusion criteria, and based on predefined laboratory 
measurements. The final step in the analysis was to 
evaluate the 99th percentile URLs for hs-cTnI in healthy 
subjects who remained after excluding those  with dys-
lipidemia. This study group consisted of 136 subjects 
(106 females and 30 males, aged 17–63). The study 
design is shown in Figure 1.
Blood sampling and laboratory analyses
Fasting venous blood samples from presumably 
healthy individuals were collected in the morning.  All 
participants had given informed consent for study par-
ticipation. Blood samples were collected into a 6 mL 
tube without anticoagulant (Becton Dickinson) to obtain 
serum and two 2 mL EDTA tubes (Becton Dickinson) 
in order to determine the HbA1c in whole blood and 
obtain plasma for determination of BNP. Serum was 
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Figure 1. The FAM study design in the Department of Laboratory Medicine, Collegium Medicum in Bydgoszcz; 
BNP — brain natriuretic peptide; HbA1c — glycated haemoglobin; eGFR — estimated glomerular filtration rate
Table 1. Control measurements at three levels
Control  
level
Troponin I  
validity range (ng/L)
Control  
value
Mean
Low 12–28 19.1
19.8
19.45
Medium 120–280 189
197
193
High 9,000–21,000 15,903.3
15,224.8
15,564
assayed immediately after centrifugation for hs-cTnI, 
cTnI, lipid profile and creatinine. HbA1c was determined 
immediately after delivery in whole blood and BNP was 
measured in fresh EDTA plasma. All measurements 
were performed on the Abbott ARCHITECT ci8200 
analyzer. The remaining material was separated in small 
aliquots and frozen at –70 °C.
Estimated GFR (eGFR) was calculated using Modi-
fication of Diet in Renal Disease (MDRD) formula which 
estimates GFR using four variables: serum creatinine, 
age, race, and gender [9]. 
Statistical analysis
The 99th percentile values were determined by 
right-sided nonparametric statistics as described in the 
CLSI C28-A3 [10]. 90% confidence intervals (CI) were 
given if possible. We decided to exclude the outlier 
observations from the analyzed population using the 
method of Reed et al. [11]. The reference intervals 
were calculated using a non-parametrical percentile 
method. Statistical analysis was performed using 
MedCalc 12.7.0.
Results
Analytical performance 
Familiarization. Initially, we measured three levels of 
STAT hsTnI Control on the Abbott ARCHITECT ci8200 
analyzer in replicates of two. None of the control mea-
surements exceeded dedicated control levels (Tab. 1).
Precision. The precision study was performed on 
each of 5 days according to CLSI guidelines (EP5-A) [5]. 
Two ARCHITECT runs were performed on each day 
with a minimum of 2 h separating the runs. Three Tro-
ponin-I controls were assayed in replicates of two on 
each run (n = 20 total reps for each control). Total im-
precision ranged from 3.1% to 5.1% and was lowest for 
the medium controls. The lowest hs-cTnI concentration 
corresponding to a total CV of 10% was 5.2 ng/L. The 
obtained results are shown in Table 2.
LoB, LoD and LoQ. Verification of LoB, LoD and 
LoQ was performed according to CLSI guidelines 
EP17-A on verifying LoB, LoD and LoQ [6]. The LoB 
was determined by twenty measurements of the zero 
calibrator. Only two replicates exceeded the claimed 
LoB. The nonparametric analysis showed the 95th 
percentile value equal to 0.1. The LoD was determined 
using twenty replicates of a sample with concentra-
tion equal to the claimed LoD. The mean LoD value 
was 1.5 ng/L (19% CV). The LoQ was determined 
using 30 replicates of a sample with a concentration 
close to the claimed LoQ. The mean LoQ value was 
4.8 (8% CV).
Dilution linearity. The linearity of cTnI assay was 
verified using low and high cTnI pools. Then we mixed 
in a 1:1 ratio high and low cTnI, and its concentration 
was determined. There was no dilution effect on the 
concentration of troponin.
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Table 2. Results of the five-day precision study
Day Control level
Low
[ng/L]
Control level
Medium
[ng/L]
Control level
High
[ng/L]
1 20.4
19.5
186.9
185.4
15,243.6
15,759.7
1 + min. 2 h 19.8
19.1
197
189
15,224.8
15,906.3
2 18.8
19.4
196.6
190.4
15,199.1
16,015.3
2 + min. 2 h 17.9
18.4
178.6
187.3
15,248.3
15,466.8
3 19.7
21.1
187.6
194.6
15,755.2
16,064.2
3 + min. 2 h 17.9
19.4
191.8
199.7
15,505.6
15,863.0
4 17.5
17.4
179.9
182.4
13,815.9
14,235.7
4 + min. 2 h 18.4
18.8
185.7
185.6
14,211.5
14,173.3
5 18.4
18.3
182.8
185.7
15,369.0
14,512.5
5 + min. 2 h 18
18.3
180.7
183.2
14,158.6
14,635.7
Mean ± SD [ng/L] 18.8 ± 0.96 187.5 ± 5.92 15118.2 ± 717.7
CV(%) 5.1 3.1 4.7
SD — standard deviation; CV — coefficient of variation
Interference testing. The evaluation of interference 
was performed using a native sample with TG in a con-
centration of about 2000 mg/dL. Pools of cTnI of various 
concentrations were mixed with a serum sample of 
a patient in order to achieve a 1000 mg/dL concentration 
of TG. There was no effect of high TG concentrations 
on cTnI concentration.
Determination of 99th percentile values
Table 3 reports 99th percentile values with 90% CI for 
the Abbott Architect STAT hs-cTnI in presumably healthy 
individuals (n = 419). When statistical criteria for outliers 
were applied, data for 3 study participants were exclud-
ed, which lowered the 99th percentile value to 12.6 ng/L 
(8.4–24.3; 90% CI) from 15.6 ng/mL (9.7–33.8; 90% CI). 
The 99th percentile values were more than twice as high 
in males compared to females. In young women and 
men (< 40 years) we observed similar 99th percentile 
values, in contrast to the older group (> 40 years), in 
which men were characterized by almost twice as high 
99th percentile value than women. 
After the introduction of laboratory screening in 
accordance with the predefined selection criteria, 
98 patients were excluded. The results for the group of 
healthy individuals are shown in Table 4. As expected, 
after  the inclusion of more restrictive criteria the 99th 
percentile values decreased to 10.6 ng/mL (8–12.9; 
90% CI). 99th percentile values for hs-cTnI were quite 
similar in healthy men and women, showing a slight 
increase in women. Unexpectedly, older women were 
characterized with higher hs-cTnI 99th percentile value, 
when compared to men.
Finally, we examined hs-cTnI 99th percentile URLs 
in subjects remaining after screening for dyslipidemia 
(Tab. 5). Following the introduction of this criterion, 
184 individuals were excluded. Of the 320 healthy indi-
viduals only 42% had normal lipid profile values. These 
group consisted of 106 women and only 30 men, and 
was characterized by the lowest 99th percentile URLs for 
hs-cTnI with a slightly higher 99th percentile value in men. 
Method comparison using  
Passing-Bablok regression
We also conducted a comparison of Abbott 
ARCHITECT STAT high sensitive Troponin-I assay 
with Abbott ARCHITECT STAT Troponin-I assay using 
Passing-Bablok linear regression, which showed that the 
two methods are comparable. We used 200 specimens 
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Table 5. 99th percentile values in healthy individuals with 
normal lipid profile
hs-cTnI [ng/L] Q2 (Q1–Q3) 99th 
percentile 
value
Healthy individuals with normal 
lipid profile  
(n = 136)
2.3 (1.9–3.2) 8.6
Women (n = 106) 2.3 (1.8–3) 7.9
Men (n = 30) 3.2 (2.3–4.6) 8.9
CI — confidence interval; hs-cTnI — high-sensitivity cardiac troponin I; 
Q1 — lower quartile; Q2 — median; Q3 — upper quartile
Table 3. 99th percentile values in presumably healthy individuals
hs-cTnI [ng/L] Q2 (Q1–Q3) 99th percentile value (90% CI)
Presumably healthy individuals (n=418) 2.7 (2.1–3.5) 12.6 (8.4–24.3)
Women (n = 265) 2.5 (2–3.1) 10.2
Men (n = 153) 3.3 (2.5–4.7) 22.1
Women < 40 years (n = 133) 2.3 (1.8–2.8) 9.1
Men < 40 years (n = 67) 2.6 (2.2–3.5) 10.9
Women ≥ 40 years (n = 132) 2.7 (2.2–3.3) 12.4
Men ≥ 40 years (n = 86) 4.0 (3–5.2) 24.3
CI — confidence interval; hs-cTnI — high-sensitivity cardiac troponin I; Q1 — lower quartile; Q2 — median; Q3 — upper quartile
Table 4. 99th percentile values in healthy individuals
hs-cTnI (ng/L) Q2 (Q1-Q3) 99th percentile value (90% CI)
Healthy individuals (n = 320) 2.6 (2.1–3.4) 10.6 (8–12.9)
Women (n = 212) 2.4 (1.9–3.1) 11.1
Men (n = 108) 3.3 (2.5–4.5) 10.7
Women < 40 years (n = 118) 2.2 (1.8–3.2) 9.4
Men < 40 years (n = 57) 2.6 (2.2–3.5) 10.9
Women ≥ 40 years (n = 94)* 2.6 (2.2–3.2) 12.9
Men ≥ 40 years (n = 49) 4.2 (3.2–4.9) 8.9
*One of the results of hs-cTnI was 12.9 ng/L, but according to the method of Reed it has not been interpreted as an outlier. 
CI — confidence interval; hs-cTnI — high-sensitivity cardiac troponin I; Q1 — lower quartile; Q2 — median; Q3 — upper quartile
with cTnI concentrations across the dynamic range of 
the ARCHITECT STAT High Sensitive Troponin-I assay. 
The results are shown in Figure 2 and Table 6.
Discussion
The FAM study conducted by our department was 
unique for several reasons. Firstly, the blood sampling 
from presumably healthy individuals was held in several 
workplaces across the region. Secondly, all measure-
ments were performed in fresh, not frozen material, 
immediately after delivery of samples to the laboratory. 
Thirdly, presumably healthy and healthy individuals 
Figure 2. The scatter diagram for comparison of the Abbott 
ARCHITECT STAT High Sensitive Troponin-I assay and 
the Abbott ARCHITECT STAT Troponin-I assay using the 
Passing-Bablok regression (with the regression line- solid 
line, the confidence interval for the regression line — dashed 
lines and identity line x = y, dotted line); hs-cTnI — high 
sensitivity cardiac troponin I; cTnI — cardiac troponin I
were selected for the reference interval study on the 
basis of a questionnaire and additional laboratory 
screening. Finally, we determined age and sex-specific 
99th percentile URLs for hs-cTnI.
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To ensure that the hs-cTnI assay is fit for purpose we 
performed studies on the LoB, LoD and LoQ values which 
demonstrated a slight variability with other studies [12, 13]. 
The lowest concentration of cTnI detected with 99% 
probability was 1.5 ng/L, whereas estimated LoB was pre-
dominantly below 0.1. The newer hs-cTn assay is more 
analytically sensitive than the previous generation of cTnI 
assays, highlighting the need for LoD to be reported [14]. 
Our study showed detectable hs-cTnI concentra-
tions in a majority of presumably healthy individuals 
(98%) in contrast to other studies [12]. The Abbott 
ARCHITECT STAT high sensitive troponin-I assay in this 
and our previous studies [15, 16] performed better in 
terms of cTnI detectability than other commercially avail-
able hs-cTn assays [17]. Of importance, these results 
should be interpreted with caution as the proportion 
of subjects with detectable concentrations of hs-cTn 
substantially depends on the characteristics of the 
population. The 99th percentile URL differed depending 
on the conditions of selection criteria applied in the pre-
sumably healthy population. The highest 99th percentile 
value was reported for presumably healthy individuals 
who participated in the study based on their health 
questionnaires. In these presumably healthy individu-
als, men were characterized by having nearly twice as 
high 99th percentile values, when compared to women, 
which was particularly evident in the older group above 
40 years of age. In the younger group of both women 
and men 99th percentile values were quite similar with 
only slight predominance in males, which may suggest 
that the differences in cTnI concentrations accumulate 
with age. In the course of further analysis presumably 
healthy individuals were screened by more stringent 
criteria, including laboratory parameters, and the 99th 
percentile values decreased with further screening. 
Similar observations concerning the influence of popu-
lation selection on the 99th  percentile reference values 
for cTn were also reported in other studies [16, 18]. 
Interestingly, in our study we showed that after the 
inclusion of more stringent selection criteria, the differ-
ences between sex and age of the healthy individuals 
were reduced. Despite the lower 99th percentile values in the female subgroup, the imprecision goal below 10% 
CV was maintained. These findings are of particular 
importance with regard to the clinical application of 
hs-cTnI using sex specific cut-offs. Lowering the diag-
nostic threshold for hs-cTnI when compared with the 
contemporary cTnI is expected to facilitate the decision 
making process in different clinical settings [18]. 
In summary, our study provides the analytical char-
acteristics of the Abbott ARCHITECT STAT high sensitive 
troponin-I immunoassay in relation to guideline recom-
mendations, along with its strengths of improved precision 
and low-end sensitivity. Additionally, we established its 99th 
percentile URLs, overall URL, age and sex-specific URLs. 
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